Company / R&D per Share
Edgewise Therapeutics, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.47
FY2025
5-year range
$0.86 / $1.47
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
#126 of 208
Health Care
What the data says
At $1.47, Edgewise Therapeutics, Inc.'s r&d per share ranks #126 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 6 years, ranging from $0.86 in FY2021 to $20.27 in FY2020.
Based on SEC 10-K filings.
1.47 in FY2025 with a 5-year CAGR of -40.8%.
Improved from $1.43 to $1.47 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +13.4%
- 5-Year CAGR
- -40.8%
- 10-Year CAGR
- -
Sector benchmark
#126 of 208 in Health CareTop 61% of 208This company $1.47 Sector average $12.19
▼
-87.9% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 7.1% year-over-year.
- Ranks #126 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.47 | +7.1% |
| FY2024 | $1.37 | -3.7% |
| FY2023 | $1.43 | +41.5% |
| FY2022 | $1.01 | +17.5% |
| FY2021 | $0.86 | -95.8% |
| FY2020 | $20.27 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026